








In vivo Imaging and Drug Storage by Quantum-Dot-Conjugated
Carbon Nanotubes**
By Yan Guo, Donglu Shi,* Hoonsung Cho, Zhongyun Dong, Amit Kulkarni, Giovanni M. Pauletti, Wei Wang,
Jie Lian, Wen Liu, Lei Ren, Qiqing Zhang, Guokui Liu, Christopher Huth, Lumin Wang, and Rodney C. EwingA specially designed carbon nanotube (CNT) is developed for use in the early detection and treatment of cancer. The key
functionalities for biomedical diagnosis and drug delivery are incorporated into the CNTs. In vivo imaging of live mice is
achieved by intravenously injecting quantum dot (QD)-conjugated CNT for the first time. With near infrared emission around
752 nm, the CNT with surface-conjugated QD (CNT-QD) exhibit a strong luminescence for non-invasive optical in vivo imaging.
CNT surface modification is achieved by a plasma polymerization approach that deposited ultra-thin acrylic acid or poly(lactic-
co-glycolic acid) (PLGA) films (3 nm) onto the nanotubes. The anticancer agent paclitaxel is loaded at 112.5 5.8mg mg1 to
PLGA-coated CNT. Cytotoxicity of this novel drug delivery system is evaluated in vitro using PC-3MM2 human prostate
carcinoma cells and quantified by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The in vivo
distribution determined by inductively coupled plasma mass spectrometry (ICP-MS) indicates CNT-QD uptake in various
organs of live animals.[*] Prof. D. Shi, Y. Guo, H. Cho, W. Wang, C. Huth
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One of the key challenges of nanotechnology in cancer
diagnosis and treatment has been the design and development
of a nanosurface structure with multiple functionalities. Due to
complexity of biological systems, these nanostructured materi-
als must have key features, such as the ability to ‘‘tune’’ or
control the surface properties. The first step is to treat the
surface with specific functional groups such that they attach to
specific biological molecules. Second, for diagnosis, the
nanoparticle should have a strong luminescence in the visible
range for in vivo imaging. Third, certain nanoparticle should
have a geometry that allows for storage and release of
treatment drugs. Finally, the nanoparticle should be biode-
gradable in order to avoid toxic effects. Thus far, there have
been few attempts to design and produce a nanostructure that
meets all of these requirements.
There are several critical issues involved in the design and
the development of such a nanoscale material. The first is the
surface functionalization by a variety of novel techniques. As
reported previously, the physical and chemical properties
of CNT can be significantly altered through chemical
surface modification, doping, and coating.[1] The surface[**] The work at University of Cincinnati (UC) was supported by a grant
from UC Institute for Nanoscale Science and Technology. The work at
Argonne National Laboratory was performed under the auspices of
the Office of Basic Energy Science, Division of Chemical Sciences, U.S.
Department of Energy, under Contract No. W-31-109-ENG-38. The
TEM analyses were conducted at the Electron Microbeam Analysis
Laboratory at the University of Michigan and supported by an NSF
NIRT grant (EAR-0403732).
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2490functionalization of CNT by a variety of organic and inorganic
species leads to the assembly of novel, hybrid nanomaterials.
Such an integrated nanosystem normally requires covalent
bonding of the CNT to another nanospecies in a predictable
manner. Recent attempts have attached gold to CNT[2] and
TiO2 nanoparticles.
[3] However, these methods resulted in
undesirable side reactions, producing large clusters of nano-
particles, which were unsuitable for biomedical applications.
We have previously described a unique plasma polymerization
process that can be used to treat the surfaces of CNT. Ultrathin
polymer films (3 nm) with functional groups were uniformly
deposited on the inner and outer surfaces of CNT.[4–7]
For biomedical diagnosis applications, one of the important
issues involves the intensity and the frequency of the emissions
from the nanoparticles. In particular, for deep tissue tumor
imaging, highly intense emissions are required at frequency
close to the near infrared range (>700 nm). Carbon nanotubes
(CNTs) are intrinsically fluorescent in the region of near
infrared,[8–10] whereas human tissues and biological fluids[11]
are practically transparent to these emissions.[12–15] However,
the emission intensities are quite low and not useful for deep
tissue or live animal imaging. In our previous research we have
succeeded in synthesizing CNT with surface-coated lumines-
cent rare-earth materials, but their emissions have low
efficiency for in vivo imaging.[16] In contrast, quantum dots
(QD), which are semiconducting nanocrystals, may be ‘‘tuned’’
based on their size and have superb optical properties,
resulting from quantum confinement effects.[17,18] They offer
high resistance to photobleaching, thus making them attractive
materials for optoelectronics[19,20] and in vivo biosensing
applications.[21] Bruchez et al.[22] and Chan and Nie[23] first
reported the use of QD conjugates for labeling biological
specimens. Subsequently, several other studies demonstrated
the labeling of whole cells and tissue sections using different
surface modifications of QD.[24–26] For both diagnosis and
treatment, the key issue here is how to combine the tubular
structure of CNT and the tunable optical properties of QD in
an intravenously (i.v.) deliverable nanoassembly.
Another issue deals with suitable requirements for in vivo
imaging. Particularly, QD must have an adequate circulating
lifetime, must show minimal non-specific deposition, and must
retain their fluorescence for a sufficiently long period. Reduced
body clearance can be achieved by coating nanoparticles with
hydrophilic polymers such as polyethylene glycol (PEG). This
augments vascular circulation time without completely elim-
inating non-specific tissue uptake.[27–29] Toxicity and biocom-
patibility have been major concerns for the use of nanomaterials
in biomedical applications.[30,31] Before clinical applications of
QD become possible, the biocompatibility of these nanopar-
ticles must be thoroughly investigated. For cell culture studies, a
biocompatible particle must be non-toxic and inert, as well as
stable over the course of an assay. Recently, Derfus et al.[32]
used cultured liver cells to determine the cytotoxicity of CdSe/
ZnS QD with various surface coatings. The results suggested
that the surface coatings must be sufficiently stable in order to
prevent oxidation of the QD surfaces, which results in thewww.afm-journal.de  2008 WILEY-VCH Verlag GmbHrelease of divalent cadmium, a known toxin and suspected
carcinogen. PEG and other biologically inert polymers may be
useful for reducing QD-associated toxicity. So far, nearly all
studies on the in vivo use of QD have reported normal organism
development and no short-term detectable toxicity.[33–38]
Paclitaxel is an antitumor agent demonstrating significant
activity in clinical trials against a variety of solid tumors.[39,40]
However, limited aqueous solubility and low therapeutic index
restrict widespread clinical application. Therefore, a diverse
array of materials has been investigated for paclitaxel delivery
systems including liposomes,[41] nanoparticles,[42] micro-
spheres,[43] and soluble polymers.[44] Among these new drug
delivery systems, polymers have attracted attention as
promising carriers for anticancer agents because of increased
stability and opportunities of surface functionalization.
Among those polymers investigated poly(lactic-co-glycolic
acid) (PLGA), which is biodegradable and FDA approved, is
preferentially used in drug delivery systems.
In this study, nanotubes with different properties and
functionalities were assembled based on a unique nanoscale
design. An idealized representation of the nanostructure design
for in vivo imaging and drug storage is schematically illustrated in
Figure 1. The hollow core and polymer-coated surfaces of the
nanotube can be used to store antitumor agents such as paclitaxel
as a consequence of non-covalent adsorption. For deep tissue
imaging, the outer surface of the nanotube is conjugated with
luminescent materials such as QD. However, both drug storage
and surface conjugation of QD depicted in Figure 1 present great
challenge to the surface functionalization of the CNTs.
In this paper, we report a novel design of a nanoassembly.
Using a unique plasma polymerization method, CNT surfaces
were functionalized with carboxyl groups that facilitated
covalent coupling of amine-containing QD. Successful in vivo
imaging and quantitative determination of paclitaxel drug
loading are described for the first time for this novel
nanoassembly. CNTs containing an ultra-thin PLGA coating
were prepared by plasma polymerization. Paclitaxel loading
efficiency on PLGA-coated CNTs was measured by high
performance liquid chromatography (HPLC). The therapeutic
efficacy of paclitaxel-loaded CNT was estimated in vitro by
quantifying drug-induced changes in viability of human PC-
3MM2 prostate carcinoma cells using the MTT assay.
2. Results and Discussion
2.1. Plasma Surface Functionalization
Plasma polymerization is an effective method for surface
functionalization of nanotubes and nanoparticles.[4–7] The
main principle of plasma polymerization is that the ionized and
excited monomer molecules created by an electrical field
bombard and react on the surface of the substrate. These
activated molecules may be etched, sputtered, or deposited
onto the substrate surface. Due to these characteristics,
the plasma technique can be used for polymer surface
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Figure 1. Schematic diagram illustrating the concept of a CNT functiona-
lized with plasma polymer coating, luminescent QD, and loaded with
anticancer drugs. The functionalized CNT can be used as biomarkers and
drug carriers.The experimental procedures and conditions for plasma
surface functionalization and characterization have been
published pre-viously.[4–7] The plasma reactor for surface
functionalization consisted mainly of a radiofrequency source,
a glass vacuum chamber, and a press gauge. Monomers were
introduced from the gas inlet during the plasma polymeriza-
tion. In this study, acrylic acid (AA), lactic acid (LA), and
glycolic acid (GA) were used as monomers for nanotube
surface functionalization.
Figure 2a and b show high-resolution transmission electron
microscopy (HRTEM) images of surface-functionalized CNT.
An ultrathin AA film of 3 nm is clearly evident on the
outer surface of the nanotube after plasma polymerizationFigure 2. a) HRTEM image showing plasma deposited AA polymer thin film (
end of the CNT, b) HRTEM image of the coating layer of PLGA on CNT by pl
c) schematic diagram outlining chemical coupling procedure of amine-conta
functionalized CNT.
Adv. Funct. Mater. 2008, 18, 2489–2497  2008 WILEY-VCH Verl(Figure 2a). The characteristic lattice fringe spacing for carbon
can be seen in contrast to the amorphous AA film (e.g., the
absence of lattice fringes). The AA film appears quite uniform,
covering the outer surface of the nanotube. Figure 2b shows a
HRTEM image of a PLGA-coating layer deposited on the
CNT by plasma polymerization. LA and GA were used as
monomers for this process. In this image, the thickness of
ultrathin coating layer is approximately 6–7 nm and also
appears as a uniform layer on the nanotube surface. For
comparison, the inner diameter of CNT used is in the order of
50–80 nm. This dimension appears particularly suitable for
drug loading with anticancer drugs of comparable molecular
size like paclitaxel.[26] The polymer films deposited on
nanotubes were characterized by surface analyses such as
time of flight secondary ion mass spectroscopy (TOFSIMS),
and results are detailed in ref.[4–7].2.2. CNT-QD Conjugation
The procedure for coupling amine-containing QD to AA-
functionalized CNT is illustrated in Figure 2c. Covalent
attachment of QD to the CNT was achieved in the presence
of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro-
chloride (EDC) and N-hydroxysuccinimide (NHS). Con-
jugation of QD with nanotubes was confirmed by char-
acterizing the microstructure of CNT-QD using HRTEM
and energy dispersive spectroscopy (EDS), respectively.
The TEM samples of CNT-QD were prepared by dispersing
the solution directly onto holy carbon films supported with
Cu grids. The TEM images of CNT-QD are shown in3 nm) near the open
asma polymerization,
ining QD to carboxyl-
ag GmbH & Co. KGaA, WeFigure 3. As can be seen in Figure. 3a,
the QD exhibits a dark contrast with an
average particle size of 5–10 nm, randomly
distributed on the surface of the nano-
tubes. In a Z-contrast TEM image of
Figure 3b, these QD appears to be bright
on the CNT surfaces with some aggre-
gated clusters. QD coverage is not uni-
form throughout the entire length of the
CNT suggesting preferential conjugation
of QD due to inhomogeneous CNT
dispersions.
Figure 3c and d show the HRTEM
images of surface-conjugated QD. As can
be seen in Figure 3c, the QD are quite
distinct from the matrix of the CNT. The
lattice images of QD and CNT are shown
in Figure 3d. In this figure, the crystalline
features of CdSe/ZnS QD deposited on
the surfaces of the CNTs can be clearly
seen. The interlayers of the CNTs are also
well resolved in both HRTEM images
(Figure 3c and d). These results suggest
that the QD are either embedded within
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Figure 3. a) TEM image of CNT with surface coupled QD, b) Z-contrast TEM image showing the
light gray QD on the CNT’s surfaces, c) and d) HRTEM images of the crystalline CdSeTe/ZnS QD
deposited on the surfaces of CNT.
Figure 4. EDS acquired from QD attached on CNT’s surface. It shows the
elemental signals from the CdSeTe/ZnS QD and CNTs.
2492Energy dispersive X-ray spectroscopy (EDS) measurements
were performed by focusing the nanosized electron probe
on CNT and QD as shown in Figure 4. Strong signals of Cd,
Se, Te, Zn, and S were observed in the spectrum acquired.
These signals suggest the identity of the QD coupled onto
the outer walls of CNT. The Cu and C peaks observed in
the spectrum can be attributed to the TEM grids and CNT
substrate. The EDS results confirm the presence of CdSe/
ZnS QD coupled onto the surface of the CNT. This is also
consistent with the results of the HRTEM (Figure 3c and d)
showing the crystalline QD on the outside surface of a
CNT.
It should be noted that no efficient coupling was observed
when QD were simply mixed with CNT in various organic
solvents (methanol, chloroform, and toluene) and in the absence
of the activating agents. There was no obvious sign of QD
degradation as studied by TEM (Figure 3). This enhanced
chemical stability is consistent with the formation of an amide
bond after covalent coupling between the amino group on the
QD and the carboxyl group on the polymer-coated CNT.
Furthermore, the preserved fluorescence of QD-modified CNT in
vivo implies limited hydrolysis of this covalent coupling product
by competent enzyme families such as peptideases.www.afm-journal.de  2008 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimFigure 5 compares the fluorescent spec-
tra of uncoupled QD and the CNT-QD
coupling product. As seen in this figure,
the maximum emission of the uncoupled
QD (dash dot line) is at 795.6 nm, which is
the consistent with the specification of this
commercial product. For CNT-conjugated
QD, the maximum emission (solid line)
was shifted to 752.5 nm, with a broad
shoulder around 650 nm. This shifting is
likely attributable to the background
emissions from the CNT or interactions
between the QD and CNT. However, an
understanding of the detailed physics of
these interactions will require further
investigation.
2.3. Drug Storage and Cytotoxicity
Study
Paclitaxel-loaded CNTs were prepared
by simple mixing of PLGA-coated CNT
with a methanolic drug solution followed
by evaporation of the organic solvent and
repeated washes in distilled water. Drug
loading efficiency was quantified by
HPLC. The recovered amount of this
anticancer agent from three independent
production batches was 112.5 5.8mg
mg1 CNT. Variation in incubation time
between drug solution and PLGA-coated
CNT from 2 to 6 h did not significantly
alter the relative loading efficiency (datanot shown). Previously, paclitaxel encapsulation into poly-
meric microparticles was reported at loading capacities
between 14 and 24mg drug mg1 carrier material.[42,43] Our
results demonstrate a five-fold increase in this loading
capacity when the polymer is deposited as a thin layer onto
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Figure 5. The fluorescent emission spectra of the uncoupledQD and CNT-
QD. The maximum peak at 795.6 nm is consistent with specifications of
this commercial QD. The blue shift from CNT-QD and a broad shoulder
around 650 nm may result from the interactions and/or background
emissions of CNT.
Figure 6. Dose-dependent effects of paclitaxel and various CNTs on
viability of human PC-3MM2 prostate cancer cells. Tumor cells
were treated for 4 days with various concentrations of paclitaxel (*),
paclitaxel-loaded, PLGA-coated CNTs (&), or PLGA-coated CNTs without
drug (&) either dissolved or dispersed in culturemedia supplemented with
3% FBS for 96 h. Each data point represents the mean of six replicate
experiments.amount recovered after one single coating/drug loading cycle
implies that drug load could be further augmented by several
sequential polymer coating/drug loading steps. This is
consistent with previous reports that identified high drug
loading capacity of soluble CNT for the anticancer drug
doxorubicin.[44] Selection of methanol as solvent in our drug
loading protocol was based on its high solubility capacity for
paclitaxel and corresponding low solubility capacity for PLGA.
As a consequence, we hypothesize that the PLGA film was not
affected by the drug loading process and that paclitaxel is
deposited by non-covalent adsorption either inside and/or
outside of the PLGA-coated CNT. It is conceivable that
conventional paclitaxel PLGA nanoparticles pre-fabricated
using the solvent evaporation technique[45] also adsorb to the
surface of uncoated or coated CNT. Although this could
constitute an alternative paclitaxel delivery system, reprodu-
cibility, and control of size distribution following adsorption of
preformed nanoparticles are considered significant technical
challenges and appear inferior to the simple drug loading
procedure of PLGA-coated CNT described in this work.
The therapeutic efficacy of paclitaxel-loaded CNT was
estimated in vitro by quantifying drug-induced changes in
viability of human PC-3MM2 prostate cancer cells using the
MTT assay. As shown in Figure 6, exposure of PC-3 human
prostate cancer cells to paclitaxel for 96 h produced a dose-
dependent inhibition of mitochondrial dehydrogenase
enzymes, which are essential for cell viability. The estimated
paclitaxel concentration leading to a 50% inhibition of cell
viability is 5 ng mL1 underlining the potency of this
anticancer agent. When exposed to paclitaxel that was loaded
onto PLGA-coated CNT, doses of 100 ng mL1 of this novel
drug delivery system are required to achieve an equivalent cell
kill of 50%. Importantly, viability of these human prostate
cancer cells in the presence of PLGA-coated CNTs that did
not contain paclitaxel was compromised only at dosesAdv. Funct. Mater. 2008, 18, 2489–2497  2008 WILEY-VCH Verl>1000 ng mL1. Whether coating with the biocompatible
PLGA polymer truly altered the cytotoxic potential of CNTs
or affected binding capacity of CNTs for the enzymatically
produced formazan dye that is used to quantify cytotoxicity in
this assay is unclear and will be subject of further investiga-
tions.[45,46] However, it appears reasonable to conclude that the
cytotoxic effect observed with drug-loaded CNTs in this in
vitro model reflects the action of paclitaxel released from
PLGA-coated carriers. Using the experimentally determined
paclitaxel concentration that kills 50% of the tumor cells in the
absence of CNTs (i.e., 5 ng mL1) and the volume of 100mL
media added per well, we can estimate a paclitaxel dose of
0.5 ng released from the coated CNTs within 96 h. Since the
average drug load is 112.5mg mg1 CNT, the estimated 0.5 ng
paclitaxel corresponds to almost 50% of the total amount of
anticancer agent incubated with the cells at the CNT dilution of
100 ng mL1. To verify this prediction, more extensive drug
release studies are required using different media in combina-
tion with cytotoxicity assessment.
2.4. In vivo Imaging and Distribution of CNT-QD
CNT-QD were injected i.v. via tail vein into mice and the
emission at 800 nm was monitored in live animals at various
time points (i.e., immediately after injection, 1, 2, 4, and 6 days)
using the Kodak 4000MM whole mouse imaging system. The in
vivo images were acquired from the front, side, and back of the
animal using the whole body mode. Mice are known to have
visible emissions that may overlap with those from the QD,
especially near 600 nm. After subcutaneous injection in mice,
the CNT-coupled QD exhibited luminescent emissions in the
visible light range. QD with longer wavelengths, however,
provide the basis for much brighter imaging, which is suitable
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Figure 7. In vivo fluorescence images of CNT-QD IV injected into nude mice and imaged after circulation at various time intervals; (a-0 to a-4) the images
taken from the side ofmice; (b-0 to b-4) from the front of mice; (c-0 to c-4) from the back ofmice, and d), e), f), g) organ images taken after having sacrificed
the mice on the 6th day of post-injection. These pictures show prominent CNT-QD uptaking in the liver, kidney, stomach, and intestine.
2494experiment, the QD with emission of 800 nm was shown to be
capable of exhibiting much brighter images as compared with
those with emissions at 600 nm at the same depth. The small
size of CNT-QD conjugates should allow efficient tissuewww.afm-journal.de  2008 WILEY-VCH Verlag GmbHperfusion and good targeting to specific sites in the tissues,
provided that the QDs remain in circulation for a long enough
time. Figure 7 shows spectral imaging results obtained from
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cence of CNT-QD in the superficial vasculature (tail veins in
Figure 7 a-1, b-1, c-1) was readily visible under the Kodak
Imaging System immediately after injection. However, at this
early post-injection stage, the CNT-QD cannot be imaged in
organs and tissues. After circulation for 2–6 days, the images
(Figure 7 a-2 to a-4, b-2 to b-4, c-2 to c-4) exhibit strong signals
of CNT-QD in several organs of live animal including liver,
kidney, stomach, and intestine. The enhanced contrast in these
images indicates that CNT-QD can be visualized against an
essentially black background, with little or no interference by
auto-fluorescence of the animal. The results indicate that QD
with emission at 800 nm are well suited for fluorescence
visualization in live animals. To confirm CNT-QD uptake in
these organs, mice were sacrificed and liver, kidney, stomach,
and intestine were harvested for ex vivo imaging (Figure 7d–g).
The strong luminescent emissions in these organs under epi-
UV illumination support our conclusions that CNT-QD may
provide significant advantages for deep tissue diagnosis.
It must be emphasized that the tested CNT did not contain
specific cell or organ targeting moieties. Therefore, the
observed biodistribution pattern following i.v. administration
reflects the results of non-specific binding and elimination
processes. It is expected, however, that coupling with specific
targeting ligands such as peptides and antibodies will alter the
biodistribution pattern.
After i.v. injection of CNT-QD, liver, kidney, stomach, and
intestine samples were collected for a period of 6 days and
analyzed by inductively coupled plasma mass spectrometry
(ICP-MS). The results of this quantitative evaluation are
presented in Figure 8. In general, CNT-QD accumulated to the
greatest extent in the liver. One day after injection, the mass of
Cd is 70.36mg g1 in liver; 2.42mg g1 in kidney; 0.86mg g1 in
stomach, and 1.00mg g1 in intestine, respectively. After
3 days, CNT-QD associated with liver, stomach, and intest-
ine significantly decreased, whereas kidney levels appearedFigure 8. In vivo distribution of CNT coupled with CdSeTe/ZnS after IV
injected in the nude mice for 1, 3, and 6 days. The liver, kidney, stomach,
and intestine of the mice were collected, respectively. The digested organ
samples were analyzed for Cd mass by using an ICP-MS.
Adv. Funct. Mater. 2008, 18, 2489–2497  2008 WILEY-VCH Verlunchanged. At the sixth day, quantified Cd amounts slightly
increased in all organs without dramatic changes in the relative
distribution (i.e., liver> kidney> stomach intestine). These
data confirm results from whole body in vivo imaging acquired
in live animals as shown in Figure 7.3. Conclusions
Based on a novel nanostructure design, QD were conjugated
onto the surfaces of the CNT for in vivo imaging. Anticancer
drug was efficiently loaded in PLGA-coated CNT. Plasma
surface modification of CNT with acidic polymers effectively
facilitated coupling of amine-containing QD. The CNT-QD
formed a fluorescent domain of emission in the desired
wavelength range. With a near infrared emission around
800 nm, the CNT-QD exhibited strong luminescence suitable
for non-invasive optical in vivo imaging. The PLGA-coated
CNT showed high loading efficiency for paclitaxel, which
demonstrated in vitro antitumor efficacy against human PC-
3MM2 prostate cancer cells. ICP-MS studies indicated
predominant CNT-QD uptake in liver, kidney, stomach, and
intestine following i.v. administration in mice. The develop-
ment of CNT-QD as a non-invasive optical in vivo imaging and
drug delivery system may have a great impact in early
detection, diagnosis, and treatment of cancer.4. Experimental
CNT-QD Conjugation: Commercial grade multiwall CNTs were
obtained from Applied Science, Inc. The CNT were chosen for their
relatively larger inner wall diameters (50–80 nm), which offer increased
capacity for drug storage. The as-produced CNT were severely
aggregated and highly hydrophobic. To modify surface properties,
CNTs were initially treated with superacid (HNO3þH2SO4). Subse-
quently, an ultra-thin AA polymer film was deposited on these
superacid-treated CNT by plasma coating using a protocol published
previously by our laboratories [4–7]. Briefly, the input power was set to
40 W, and the system pressure was adjusted from 150 to 400 mTorr.
Plasma treatment time was 30 min per batch. After surface
functionalization, the CNT were dispersed in phosphate-buffered
saline solution (PBS) and sonicated for 30 min. The as-synthesized
CNTs were too long for in vivo circulation. To select CNTs in a more
desirable size range around 200–400 nm, a sequential filtration protocol
was applied using 25 mm nylon syringe filters with pore sizes of 0.45 and
0.22mm, respectively (Thermo Fisher Scientific, Inc., Pittsburgh, PA).
A stable suspension of CNT collected from the 0.22mm filter in PBS
was used for i.v. administration in mice.
Amine-functionalized Qdot 800 ITK QD with emission wavelength
of 800 nm were supplied by Invitrogen Corporation (Carlsbad, CA,
Product # Q21571MP, 8mM solution). QD have a core of CdSeTe and a
shell of ZnS with a surface coating of amino PEG. Coupling of the
amine-containing QD to the carboxyl-functionalized CNT was
achieved using standard carbodiimide chemistry[47] and the procedure
is illustrated in Figure 2c. Briefly, 10mg of CNT were dispersed into
100mL PBS and combined with 200mL of a solution containing 0.5 M
EDC and 1 M NHS in PBS. Following a 30 min activation at
room temperature 20mL (0.16 nmol) of the commercial, amino-
functionalized QD suspension in borate buffer, pH 8.3 were added, and
the CNT-QD coupling mixture was incubated at 50 8C for 12 h. The
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249612 000 rpm for 3 min, and rinsed three times with PBS using
centrifugation and decantation. The final CNT-QD preparation was
re-suspended into 200mL of PBS.
Luminescence Spectroscopy: In order to obtain the emission
spectrum of the sample, 475 nm LED was used as the exciting source.
A 550 nm long path filter was placed into the system to block the
emissions from the diode. The fluorescence emission was dispersed by a
SPEX 1704 monochromator and detected with a cooled RCA C31034
photomultiplier. An electric motor driving chopper combined with
SR830 DSP lock-in amplifier was used to improve the signal/noise ratio
of the data. Both measurements were performed at room temperature
and recorded using our own software.
Paclitaxel Storage in PLGA-coated CNTs and Cytotoxicity Study:
PLGA-coated CNT were prepared by plasma polymerization and
washed twice with methanol. Drug loading was performed by
incubating 20–25 mg of PLGA-coated CNT with 11.4–14.2 mL of a
0.7 mg mL1 paclitaxel stock solution prepared in methanol at a final
CNT/drug ratio of 2.5 w/w. The suspension was sonicating with an
energy output of 5 W in a pulse mode for 5 min under cooling and
vacuum dried. Removal of the organic solvent under these conditions
was completed within 2 h. Preparations were washed at least three
times with 10 mL of distilled water followed by centrifugation. After
the last wash, paclitaxel-loaded CNT suspended in water were frozen
and lyophilized until further use. The amount of paclitaxel loaded onto
PLGA-coated CNT was quantified by HPLC after back extraction of
the drug from CNT using methanol. Drug-loaded CNT (1.5–2 mg) was
suspended in 5 mL of methanol, sonicated for 10 min under cooling,
and centrifuged. The supernatant organic phase was removed, and the
procedure was repeated twice. An aliquot of the pooled extraction
solutions was evaporate to dryness under N2 and reconstituted in
acetonitrile. Samples (10mL) were injected into a Varian ProStar
HPLC system equipped with an UV detector. Isocratic chromato-
graphy was performed on a Dynamax C18 column using acetonitrile/
water (60:40) as a mobile phase. Paclitaxel was detected at l¼ 220 nm
and quantified using a standard curve between 0 and 250mg mL1.
Drug loading was expressed as amount of drug per weight of carrier
material (i.e., mg paclitaxel mg1 CNT). Mass balance of this drug
loading and backextraction protocol was verified by separate
incubation of fabrication containers and drug-loaded CNT with
acetonitrile that exhibit high solubility capacity for both paclitaxel
and PLGA. Quantitative evaluation of these samples revealed 20–30%
drug loss in fabrication containers and >90% recovery of drug after the
described backextraction protocol.
PC-3MM2 human prostate cancer cells were cultured in Eagle’s
minimal essential medium (EMEM) supplemented with 5% FBS, non-
essential amino acids, sodium pyruvate, vitamin A, and glutamine at
37 8C in a humidified incubator under an atmosphere of 5% CO2. Cells
in exponential growth phase were harvested by a 2 min treatment with
a 0.25% trypsin/0.02% EDTA solution and maintained by periodic
dilutions with a fresh medium. Effects of paclitaxel solutions and
paclitaxel-loaded CNT suspensions on in vitro cell viability were
evaluated using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide] assay. Tumor cells were plated in 100mL EMEM-1%
FBS at a density of 1000 cells in a 96-well plate. After an overnight
incubation culture period, cells were exposed for 4 days with different
concentrations of paclitaxel or different amounts of paclitaxel-loaded
CNT at 37 8C under standard cell culture conditions. EMEM-1% FBS
was used as vehicle control. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (2 mg mL1 in PBS) was added to the cultures
at 0.05 mL per well during the final 2 h of incubation. The medium was
then carefully removed, and the dark blue formazan was dissolved in
100mL per well of DMSO. The absorbance of each well was measured
with a FluoStar Optima multidetection microplate reader (BMG
Labtechnologies, Durham, NC) at 570 nm. The percentages cell
viability were calculated according to: (Abs 570 nm of treated group/
Abs 570 nm of control group)100.
In Vivo Imaging of CNT-QD: Whole body images were acquired
using a Kodak4000 MM Whole-Mouse Image Station. Excitation andwww.afm-journal.de  2008 WILEY-VCH Verlag GmbHemission filters were 720 and 790 nm, respectively, centered on the
emission maxima of the QD. The excitation light was from an UV lamp
with the 10 zoom lens, and the exposure time was 2 min. The dosage
used in this study was 5mg of CNT coupled with 0.08 nmol of QD and
dispersed in 100mL PBS. Nu/nu nude mice, obtained from the National
Cancer Institute, MD, were 6–8 weeks old and typically weigh 18 g.
Mice were anesthetized for imaging by beutal saline intraperitoneally.
The mice used for in vivo imaging were maintained in a facility
approved by the American Association for Accreditation of Labora-
tory Animal Care and in accordance with current regulations and
standards of the US Department of Agriculture, US Department of
Health and Human Services and National Institute of Health. This
study was approved by Institutional Animal Use and Care Committee
(IACUC) at the University of Cincinnati (OH).
Distribution of CNT-QD In Vivo: After UV irradiation for 30 min,
100mL of CNT-QD (5mg of CNT coupled with 0.08 nmol of QD) were
injected i.v. into nude mice via the tail vein. The liver, kidney, stomach,
and intestine of the mice were collected for 6 days and analyzed by ICP-
MS. Each organ sample was washed thoroughly with deionized water
and dried for 4 h at 120 8C. Each experiment was repeated three times.
In order to prepare ICP-MS solution, the organ samples were digested
by a microwave accelerated reaction system (CEM MARS 240/50),
following standard protocols. The digested solutions were then
qualitatively analyzed for the mass of Cd by using an ICP-MS (Perkin
Elmer, SCIEX ELAN DRC-e). Each sample was analyzed five times.
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